A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have type 2 diabetes
Have a BMI of ≥27 kilograms per square meter (kg/m2)
Have had a stable body weight for the 3 months prior to randomization (\<5% body weight gain and/or loss)
You may not be if
Have a prior or planned surgical treatment for obesity,
Have type 1 diabetes, latent autoimmune diabetes, or history of ketoacidosis or hyperosmolar state or coma
Have poorly controlled hypertension
Have any of the following cardiovascular conditions within 3 months prior to screening:
* acute myocardial infarction
* cerebrovascular accident (stroke)
* unstable angina, or
* hospitalization due to congestive heart failure
Have a history of New York Heart Association (NYHA) Functional Classification III or IV congestive heart failure
Have ongoing or a history of frequent intermittent or chronic tachyarrhythmia syndromes
Have ongoing or a history of bradyarrhythmias other than sinus bradycardia
Have renal impairment
Have a history of symptomatic gallbladder disease within the past 2 years
Have signs and symptoms of any liver disease
Have a disease or condition known to cause gastrointestinal malabsorption or a known clinically significant gastric emptying abnormality
Have a history of acute or chronic pancreatitis
Currently taking or have taken medications that may cause significant weight gain or promote weight loss within 3 months prior to screening
Clareo Health | A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes
